When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Ray Therapeutics located?

Ray Therapeutics is headquartered in Berkeley, United States.

Who is the current CEO of Ray Therapeutics?

Paul Bresge of Ray Therapeutics. They have also founded 1 company.

Is Ray Therapeutics a funded company?

Ray Therapeutics is a funded company, having raised a total of $231M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 04, 2022.

When was the latest funding round of Ray Therapeutics?

Ray Therapeutics' latest funding was a $***** Series B round on Apr 21, 2026, with participation from 11 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.01B in funding in 2026 to date.

Where does Ray Therapeutics rank among its competitors?

Ray Therapeutics ranks 18th amongst 124 active competitors, of which 47 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Ray Therapeutics, which secured $125M in Apr, 2026.

Who are the top competitors of Ray Therapeutics?

Ray Therapeutics' top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Ray Therapeutics secured the most recent funding round in April, 2026.

Ray Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Ray Therapeutics is a series B company based in Berkeley (United States), founded in 2021 by Paul Bresge. It operates as a Developer of therapeutics for degenerative retinal diseases. Ray Therapeutics has raised $231M in funding from investors like 4Bio Capital, Janus Henderson Investors and Novo Holdings. The company has 124 active competitors, including 47 funded and 24 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.

Company Details

Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.

Website: raytherapeutics.com
Email ID: *****@raytherapeutics.com

Key Metrics

Founded Year

2021

Location

Berkeley, United States

Stage

Series B

Total Funding

$231M in 6 rounds

Latest Funding Round

Series B, Apr 21, 2026, $*****

Investors

4Bio Capital & 12 more

Ranked

18^th among 124 active competitors

Similar Companies

4D Molecular Therapeutics & 128 more

View Ray Therapeutics' full profile

Ray Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ray Therapeutics, Inc. CIN: 862056423 , United States, Active	Dec 31, 2020	-	16 (As on Dec 31, 2024)	-

Ray Therapeutics has raised a total funding of $231M over 6 rounds. Its first funding round was on Jan 04, 2022. Its latest funding round was a Series B round on Apr 21, 2026 for $*****. 11 investors participated in its latest round. Ray Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Ray Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2026	5081486	Series B	6538065	1776471	3310527	5429726
Apr 24, 2025	9945471	Grant (prize money)	5866669	7753813	5191276	CIRM
Nov 13, 2023	6537336	Grant (prize money)	8419870	2584886	6787897	State of California

Access funding benchmarks and valuations. Sign up today!

View details of Ray Therapeutics's funding rounds and investors

The founders of Ray Therapeutics is Paul Bresge. Paul Bresge is the CEO of Ray Therapeutics.

Here are the details of Ray Therapeutics' key team members:

Paul Bresge: Co-Founder & CEO of Ray Therapeutics.
Contact Info: 1 email address

View details of Ray Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ray Therapeutics include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Ray Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	68/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	66/100
5th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
6th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
7th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Marshall Wace & 10 others	62/100
8th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, Avoro Capital & 12 others	61/100
9th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	61/100
10th	Opus Genetics 2021, Durham (United States), Public	Developer of gene therapies to treat retinal degenerative diseases	$23.5M	RD Fund, Bios Partners & 2 others	59/100
18th	Ray Therapeutics 2021, Berkeley (United States), Series B	Developer of therapeutics for degenerative retinal diseases	$231M	Marshall Wace, Deerfield & 11 others	57/100